Hyloris Lines Up FDA Filing For Valacyclovir Oral Suspension

Also Adds Rights In New Markets As Clinical Trial Delivers Positive Results

 
• By Dave Wallace

As Hyloris revealed positive clinical trial results for valacyclovir oral suspension, the firm also disclosed plans for a US filing by the end of 2024 as well as expanded rights to the product in additional markets.

Sign outside of FDA's headquarters in White Oak, MD
Hyloris is planning an FDA filing by the end of the year • Source: Alamy

More from Value Added Medicines

More from Products